[MicrobiotiX (BioSpace)] MicrobiotiX announced the successful completion of the sentinel cohort of its first-in-human Phase I clinical trial evaluating MP101 in patients with pneumonia caused by Pseudomonas aeruginosa.

[Nature] The US FDA granted approval to Moderna’s mRNA-based flu vaccine, mFLUSIVA, for adults aged 50–64, and accelerated approval for adults aged 65 and older.

[Nature Reviews Disease Primers] The spectrum of diseases caused by Methicillin-resistant Staphylococcus aureus range from uncomplicated skin and soft-tissue infections to life-threatening invasive infections such as bacteraemia, pneumonia, osteomyelitis and endocarditis.

[Nature Immunology] Researchers isolated and characterized hundreds of recall and de novo neutralizing monoclonal antibodies after sequential exposures to SARS-CoV-2 variants in ancestral-imprinted humans.

[Proceedings of the National Academy of Sciences of the United States of America] Scientists applied DAb-seq, a high-throughput method that combines single-cell DNA and surface protein sequencing, to profile ~527,000 CD4 T cells from the blood of six individuals on antiretroviral therapy.

[Cell Host & Microbe] Investigators presented a systematic proteomic characterization of the chromatin domains in Plasmodium falciparum, an ancient human pathogen with a unique genome composition and epigenetic blueprint.

[Cell Reports Medicine] Leveraging combinatorial tetramers, scientists profiled CD8+ T cells specific for SARS-CoV-2, as well as those for cytomegalovirus and Epstein-Barr virus, herpesviruses implicated in COVID-19 pathogenesis.

[Proceedings of the National Academy of Sciences of the United States of America] Researchers studied the origin and spread of SARS-CoV-2 variants whose mutations reduce presentation by the human leukocyte antigen (HLA) class I alleles common in human populations.

[Nature Microbiology] Researchers utilized DNA and RNA platforms to compare virus-like particle vaccines with premembrane and ZIKV envelope expressed either in the wild-type form or with fusion loop mutations, which limit antibody-dependent enhancement of infection.

[Cell Stem Cell] Investigators presented an approach that involves differentiating universal major histocompatibility complex (MHC)-deficient hiPSCs into CCR7⁺ migratory dendritic cells.

[Lab on a Chip] The authors presented a novel microphysiological system using a compartmentalized microfluidic device to integrate co-cultured hiPSC-derived cardiomyocytes and sympathetic neurons.

[Stem Cell Reports] The therapeutic potential of autologous-derived dendritic cells is challenged by the number and quality produced and the diversity of antigens presented. Researchers addressed this limitation by developing a protocol to generate induced pruriceptors from hiPSCs.